BeiGene's tislelizumab approved in Europe for lung cancer

The European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use.

Developed by Sino-American oncology specialist BeiGene (HKEX: 06160), tislelizumab was approved for these NSCLC indications under the brand name Tizveni.

“Tislelizumab is foundational for BeiGene’s solid tumor portfolio and has demonstrated its potential across multiple…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.• Daily roundup of key events in pharma and biotech.• Monthly in-depth briefings on Boardroom appointments and M&A news.• Choose from a cost-effective annual package or a flexible monthly subscription.